Hyloris reports results for the full year 2021 : vimarsana.c

Added 4 additional innovative product candidates Strong growth in H2 leading to total revenues of €3.1 million Significant expansion of commercial footprint of Maxigesic® IV ... | March 16, 2022

Related Keywords

Belgium , Norway , Malaysia , Australia , United Kingdom , Luxembourg , Austria , Canada , Woman , Bahrain , Pakistan , Germany , Mexico , Iceland , Thailand , New Zealand , Denmark , Netherlands , Israel , Albania , Italy , Ireland , South Korea , Panama , France , Spain , Cyprus , Greece , Belgian , Thomas Jacobsen , Vaneltix Pharma , Vulvovaginal Candidiasis , Olivier Declercq , Abid Irshad , Jean Luc Vandebroek , Stijn Van Rompay , Chris Buyse , Delveinsight Market Research , Alter Pharma Group , Department Of Radiology , University Of South Carolina College Medicine , Linkedin , Hyloris Pharmaceuticals , Leukemia Lymphoma Society , Academic Pharmaceuticals , Hyloris Pharmaceuticals Sa Euronext Brussels , Business Development , Euronext Brussels , Chief Executive Officer , Delveinsight Market , Domiphen Bromide , Purna Female Healthcare , Recurrent Vulvovaginal Candidiasis , Pleco Therapeutics , Healthcare April , Lymphoma Society , Associate Professor , Medical University , South Carolina College , Fusidic Acid Cream , Fusidic Acid , Chief Business Development Officer , Chief Financial Officer , Managing Director , Initial Public , Hyloris Pharmaceuticals Sa Stock Exchange , News , Information , Press Release , Dded , , Dditional , Nnovative , Product , Candidates , Strong , Growth , N , 2 , Reading , O , Total , Revenues , F , Billion , Significant , Expansion , Commercial , Footprint , V Hyl Be0974363955 ,